It is well known that thyroid hormones modulate lipoprotein metabolism. Thus, the presence of clinical or subclinical hyperthyroidism may in¯uence lipid parameters of dyslipidaemic patients and the ef®cacy of hypolipidaemic therapy. Here we present a patient with mixed hyperlipidaemia whose impressive improvement of his lipid pro®le following cipro®brate administration pointed towards the diagnosis of asymptomatic underlying subclinical hyperthyroidism.
Introduction
It is well known that thyroid hormones modulate lipoprotein metabolism [1±3] . In fact, compared to controls, thyrotoxic patients exhibit signi®cantly lower amounts of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, apolipoprotein B, and Lp(a) and higher ApoA1 levels [4] . Additionally, hyperthyroidism should be considered as a possible cause of secondary decreased LDL levels (hypobetalipoproteinaemia) [5] .Thus, the presence of clinical or even subclinical hyperthyroidism occasionally encountered in the population may in¯uence the lipid pro®le of dyslipidaemic patients and the ef®cacy of hypolipidaemic therapy. Here we present a patient with mixed hyperlipidaemia whose impressive improvement of his lipid pro®le following cipro®brate administration pointed towards the diagnosis of asymptomatic underlying hyperthyroidism.
Case report
A 52 year-old man visited the outpatient lipid clinic for medical consultation. He had a long-term history of mixed hyperlipidaemia with total cholesterol and triglyceride levels ranging between 280 and 340 mg/dl and 200±300 mg/dl, respectively. Thyroid function tests had not been performed. Cipro®brate 100 mg/day was given 2 years ago, and he reported a signi®cant amelioration of his lipid pro®le. In fact, in three successive lipid determinations total cholesterol ranged between 160 and 190 mg/dl, LDL cholesterol between 100 and 120 mg/dl, triglycerides between 140 and 160 mg/dl, and HDL cholesterol between 34 and 38 mg/ dl. He also stated a weight loss of about 3 kg, which was ascribed to dietary energy restriction. On examination, body weight was 62 kg, BMI 24.5 kg/m 2 , blood pressure 130/80 mmHg, heart rate 90/min, total cholesterol 172 mg/dl, LDL cholesterol 106 mg/dl, HDL cholesterol 36 mg/dl, and triglycerides 148 mg/dl. The thyroid stimulating hormone (TSH) levels, which we measured as part of the routine investigation in middle-aged patients with dyslipidaemia, but mainly because of the impressive lipid changes after cipro®brate administration, was repeatedly 0.01 mU/ml. 
Discussion
Our patient ful®lled the criteria for the diagnosis of subclinical hyperthyroidism, since he had a repeated subnormal TSH but normal free T3 and free T4 levels, in the absence of interfering drugs, concurrent non-thyroidal illness, or evidence of a pituitary or hypothalamic disorder [6, 7] . The detection of the profoundly low TSH levels measured by a third generation assay with a detection limit of 0.01 mU/ml can exclude non-thyroidal illnesses, which very rarely suppress TSH levels to this degree [8] . Finally, an autonomously functioning thyroid adenoma was found leading to a progression towards overt hyperthyroidism. We have shown that subclinical hyperthyroidism can in¯uence the ef®cacy of hypolipidaemic therapy. In fact, the marked improvement in this patient's lipid pro®le and especially the decrease in total and LDL cholesterol levels after cipro®brate administration±which normally in¯uences LDL cholesterol levels slightly±is possibly related to the thyroid function abnormality. This statement is strengthened by the increase in serum lipid parameters following radioactive iodine therapy. In a previous study of T4-treated hypothyroid patients, raising the dose of T4 just enough to cause subclinical thyrotoxicosis resulted in a signi®cant decrease in total and LDL cholesterol levels [9] . Even though changes in triglyceride levels are not consistently reported in patients with thyrotoxicosis, one cannot exclude the possibility that the marked decrease in serum triglycerides is not only due to cipro®brate administration but also to the subclinical hyperthyroidism. In fact, in some cases with hypothyroidism, hypertriglyceridaemia is observed due to decreased triglyceride clearance probably mediated via decreased lipoprotein lipase activity [10, 11] . Additionally, a small increase in serum triglycerides was evident after the correction of thyroid function abnormality. Our data emphasise the importance of systemic clinical and laboratory screening, including thyroid function tests, in patients attended a lipid clinic. Furthermore, unexpected changes in serum lipid pro®le should be an alarming sign pointing to the diagnosis of an underlying disease, such as thyroid function abnormalities.
